India's Aurobindo Pharma First Major Generic Drugmaker To Join UNITAID's Medicines Patent Pool

“India’s Aurobindo Pharma has become the first major generic drugmaker to join” the Medicines Patent Pool, launched by the UNITAID health financing system and “designed to make HIV/AIDS treatments more widely available to the poor,” Reuters reports. “The Medicines Patent Pool said on Tuesday the agreement would allow Aurobindo to make a range of AIDS drugs licensed to the pool by Gilead Sciences, the leading maker of HIV drugs, in July,” according to the news service. “Aurobindo has also elected to take advantage of a key provision in the pool’s licenses in order to sell one drug, tenofovir, to a wide range of countries without paying royalties,” Reuters writes, adding, “These could include several middle-income countries such as Argentina, Brazil, Chile, Colombia, Malaysia, the Philippines, Ukraine and Uruguay” (Hirschler, 10/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.